Radioiodine therapy for thyroid volume reduction of large goitres

Nuclear Medicine Communications

Volumn 30, Issue 6, 2009, Pages 466-471

  Bachmann, Juliane ^a   Kobe, Carsten ^a   Bor, Seher ^a   Rahlff, Ilka ^a   Dietlein, Markus ^a   Schicha, Harald ^a   Schmidt, Matthias ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Goitres; Magnetic resonance imaging; Radioiodine therapy; Thyroid volume reduction

Indexed keywords

ANTITHYROID AGENT; IODINE 131; LEVOTHYROXINE; THYROTROPIN;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CONTROL GROUP; CONTROLLED STUDY; DOSIMETRY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GOITER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RETROSPECTIVE STUDY; THYROID FUNCTION TEST; THYROID GLAND; THYROID SCINTISCANNING; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; ULTRASOUND; WHOLE BODY RADIATION;

AGED; AGED, 80 AND OVER; FEMALE; GOITER; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOMETRY; RECURRENCE; RETROSPECTIVE STUDIES; THYROID GLAND; TREATMENT OUTCOME;

EID: 67649669875     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832b5ccc     Document Type: Article

References (34)

1. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, Schumm-Draeger PM. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96 278 unselected employees. Thyroid 2004; 14:926-932.
2. Hampel R, Zöllner H, Glass A, Schönebeck R. No influence of urinary nitrate excretion on the goitre prevalence in Germany. Med Klin 2003; 98:547-551.
3. Andersson M, de Benoist B, Darnton-Hill I, Delange F, editors. Iodine deficiency in Europe: a continuing public health problem. France: WHO; 2007.
4. Meng W, Meng S, Hampel R, Ventz M, Zeisler A. Results of thyroid hormone therapy in bland struma. Z Gesamte Inn Med 1982; 37:540-542.
5. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metabol 2001; 86:998-1005.
6. Brenta G, Schnitman M, Fretes O, Facco E, Gurfinkel M, Damilano S, ef al. Comparative efficacy and side effects of the treatment of euthyreoid goiter with levo-thyroxine or triiodthyroacetic acid. J Clin Endocrinol Metabol 2003; 88:5287-5292.
7. Kreissl M, Tiemann M, Hanscheid H, Rendl J, Reiners C. Vergleich der Wirksamkeit zweier verschieden dosierter Levothyroxin-lodid-Kombinationen in der Therapie der euthyreoten diffusen Struma. Dtsch Med Wschr 2001; 126:227-231.
8. GruBendorf M, Vaupel R, Reiners C, Wegscheider K. Die LISA-Studie- eine randomisierte, doppelblinde, vierarmige, plazebokontrollierte, multizentrische Studie an 1000 Patienten iiber die medikamentose Therapie der Struma in Deutschland. Med Klin 2005; 100:542-546.
9. Dietlein M, Dressier J, Griinwald F, Leisner B, Moser E, Reiners C, e( al. Deutsche Gesellschaft fur Nuklearmedizin. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 2007; 46:220-223.
10. Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegediis L Management of the nontoxic mulitnodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 2000; 53:5-12.
11. Le Moli R, Wesche M, Tiel-van Buul M, Wiersinga WM. Determinants of longterm outcome of radioiodine therapy or sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1999; 50:783-789.
12. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegediis L. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metabol 1999; 84:3636-3641.
13. Bonnema SJ, Nielsen VE, Hegediis L. Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur J Endocrinol 2004; 150:439-445.
14. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994; 121:757-762.
15. Dietlein M, Dressier J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H. Deutsche Gesellschaft fiir Nuklearmedizin; Deutsche Gesellschaft fiir Medizinische Physik. Procedure guideline for radioiodine test (version 3). Nuklearmedizin 2007; 46:198-202.
16. Hänscheid H, LaBmann M, Börner W. Aktivitätsbestimmung vor Radioiodtherapie der Schilddriise-Ein Vorschlag zur Minimierung von Aufwand und Fehler. Nuklearmedizin 1993; 2:A128.
17. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993; 34:1632-1638.
18. Eschner W, Moka D. Pra- und posttherapeutische Dosimetrie bei der Radioidtherapie benigner Schilddriisenerkrankungen. Der Nuklearmediziner 2007; 27:90-97.
19. Massaro F, Vera L, Schiavo M, Lagasio C, Caputo M, Bagnasco M, et al. Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose. J Endocrinol Invest 2007; 30:318-322.
20. Bonnema SJ, Andersen PB, Knudsen DU, Hegediis L. MR Imaging of large multinodular goiters: observer agreement on volume versus observer disagreement on dimension of the involved trachea. AJR 2002; 179:259-266.
21. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, ef al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation on older persons. N Engl J Med 1994; 331:1249-1252.
22. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a metaanalysis. J Clin Endocrinol Metabol 1996; 81:4278-4289.
23. Fast S, Bonnema SJ, Hegediis L. The majority of Danish non toxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol 2008; 69:653-658.
24. Dietlein M, Dederichs B, Kobe C, Theissen P, Schmidt M, Schicha H. Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 2006; 45:21-34.
25. Moalem J, Suh I, Duh Q-Y. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg 2008; 32:1301-1312.
26. Thomusch O, Sekulla C, Ukkat J, Gastinger L, Lippert H, Dralle H. Qualitätssicherung benigner und maligner Strumen. Zentralbl Chir 2001; 126:667-671.
27. Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 2006; 16:281-288.
28. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, See-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ 1993; 307:828-832.
29. Nygaard B, Farber J, Veje A, Hansen JE. Thyroid volume and function after 1311 treatment of diffuse non-toxic goitre. Clin Endocrinol (Oxf) 1997; 46:493-496.
30. Hegedüs L, Bennedbaek FN. Radioiodine for non-toxic diffuse goitre. Lancet 1997; 350:409-410.
31. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489-499.
32. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83:1072-1077.
33. Bonnema SJ, Nielsen VE, Boel-Jergensen H, Grupe P, Andersen PB, Bastholt L, Hegedüs L. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goitre: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007; 92:3424-3428.
34. Bonnema SJ, Nielsen VE, Boel-Jergensen H, Grupe P, Andersen PB, Bastholt L, Hegedüs L. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab 2008; 93:3981-3984.